TIMI Study Group
@TIMIStudyGroup
Followers
4K
Following
109
Media
168
Statuses
2K
Providing the latest news and research from the TIMI Study Group, an ARO affiliated with Brigham and Women’s Hospital and Harvard Medical School.
Boston, MA
Joined September 2013
TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online. https://t.co/NXuasBCjV4
timi.org
Visit the post for more.
1
11
62
Drs. Michelle O'Donoghue and Marc Sabatine discuss the ESC Dyslipidemia Guideline Update @escardio @DrM_ODonoghue
https://t.co/5qw3vhC3A0
0
3
4
Icosapent ethyl reduces MI across MI subtypes and sizes of MI in statin-treated patients with elevated TGs at increased CV risk @rgiugliano
https://t.co/MLpbEW4Jls
academic.oup.com
AbstractAims. We studied the efficacy and safety of icosapent ethyl (IPE) 4g daily in reducing the risk of myocardial infarction (MI) across different MI s
0
3
10
GARDEN-TIMI 74: Ponsegromab Fails to Achieve Primary Endpoints, May Actually Worsen HF @ddbergmd
https://t.co/6TFqfou7t3
0
5
15
Last day at @HFSA #HFSA25 Excellent session by Dr. Berg (@ddbergMD, @TIMIStudyGroup) on GDF-15 neutralization in heart failure patients, followed by insightful discussions led by @coconnormd, and another interesting presentation and discussion by @neallakdawala and @noshreza.
0
2
14
GOLDILOX-TIMI 69 results now in Nat Med. No effects of LOX-1 inhibition on coronary plaque volume. @DrM_ODonoghue
https://t.co/My1FmLPNPO
0
1
3
Fueled by thoughtful questions from @AliceYYCheng, I had the honor of engaging in a fun and insightful discussion on our recent FOURIER-T1DM project! @TIMIStudyGroup #LawrenceLeiter #MarcSabatine
🚨 A new month, a new Care on Air! Where #podcast hosts Michael R. Rickels, MD, MS & @AliceYYCheng discuss the latest and greatest of Diabetes Care. 🎧 https://t.co/o4SOmkE1MO In this ep: Insights from the FOURIER Trial w/ @YumiKangEndo, the STRIDE Trial w/ @NedaRasouli2,
0
1
1
In patients with atrial fibrillation on VKAs, the #DOAC Score stratified risk for major bleeding and showed stronger predictive performance than HAS-BLED, with modest overall discrimination. @RahulAggarwalMD @rgiugliano #ESCCongress
0
13
40
Abelacimab consistently reduces bleeding vs. rivaroxaban irrespective of CrCl or rivaroxaban dose reduction. @SidPatelMD #ESCCongress Full manuscript available at: https://t.co/yL57hgPDv6
1
6
22
OAC-naïve patients experience higher rates of bleeding. In #AZALEA-TIMI 71, #abelacimab consistently reduced major/CRNM bleeding vs. rivaroxaban irrespective of prior OAC status or type of OAC (DOAC or VKA). @SidPatelMD #ESCCongress
1
7
21
In AFib pts ≥80 yrs meeting dose-↓ criteria, pts randomized to edoxaban 15 vs. 30 mg had comparable rates of stroke/SE. Edox 15 mg led to a trend toward ↑ ischemic strokes but ↓ major & intracranial bleeds; supported by PK/PD analysis. @AndreZimerman @rgiugliano #ESCCongress
2
4
22
See @SidPatelMD speak on renal function and factor XI inhibition in a pre-specified analysis of AZALEA-TIMI 71, in 24 hours in Science Box 3 #abelacimab #ESCCongress
0
0
1